SCHEMBL3864684

SCHEMBL3864684

C#CCOc1nc(Nc2cc(NC)cc(C(=O)O)c2)ncc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 6/20 0.41
CDK2 P24941 6/20 0.41
KDR P35968 5/20 0.41
CHEK1 O14757 1/20 0.41
NTRK2 Q16620 1/20 0.41
ULK1 O75385 4/20 0.40
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
ULK2 Q8IYT8 1/20 0.39
CCNB1 P14635 3/20 0.39
CCNE1 P24864 3/20 0.39
GSK3B P49841 1/20 0.39
EGFR P00533 2/20 0.38
BTK Q06187 1/20 0.38
ITK Q08881 1/20 0.37
CA2 P00918 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LRRK2 Q5S007 2/20 0.34
MAPK8 P45983 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3867438 0.87 CDK1 (0.38) CDK1CDK2KDRCHEK1NTRK2
SCHEMBL3864685 0.81 ULK1 (0.40) CDK1CDK2KDRCHEK1NTRK2
SCHEMBL3864679 0.80 ULK1 (0.39) CDK1CDK2KDRCHEK1NTRK2
SCHEMBL3865627 0.79 CDK1 (0.39) CDK1CDK2KDRCHEK1NTRK2
SCHEMBL4023231 0.78 CDK2 (0.49) CDK1CDK2KDRCHEK1NTRK2
SCHEMBL13897453 0.78 GPR142 (0.36) CDK1CDK2KDRCHEK1NTRK2
SCHEMBL6451895 0.78 CDK2 (0.48) CDK1CDK2KDRCHEK1NTRK2
SCHEMBL13897479 0.77 PKM (0.38) CDK1CDK2KDRULK1PRKAA2
SCHEMBL3869603 0.76 SMN1; SMN2 (0.56) EGFRBTKITKKDM4EALDH1A1
SCHEMBL3871525 0.76 HDAC8 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 US disclosed
EP-1565446-A1 CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-08-24 EP disclosed
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-09-23 US disclosed
WO-2004048343-A1 CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents DCK, PDPK1, DTYMK CDK1 237/4885CDK2 105/4885KDR 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.